title: Renal biopsy findings and followup of renal function in rheumatoid arthritis patients treated with cyclosporin A. An update from the International Kidney Biopsy Registry.
abstract: OBJECTIVE
  To review data from the International Kidney Biopsy Registry, which describes the occurrence of cyclosporin A (CSA)-induced nephropathy, and to discuss the potential risk factors for its development.
  
  
  METHODS
  The report examines data on a total of 60 first and 14 second renal biopsies performed in rheumatoid arthritis (RA) patients treated with CSA for up to 87 months.
  
  
  RESULTS
  Five of the 60 patients with RA included in the Biopsy Registry had findings consistent with CSA-induced nephropathy at first biopsy. One further patient had such findings at second biopsy. Of the 22 patients who started CSA at dosages < 4 mg/kg/day and subsequently received dosages no higher than 5 mg/kg/ day, none developed CSA-induced nephropathy. Continuous assessment of renal function did not show any evidence of deterioration over time in patients maintained on low-dose CSA.
  
  
  CONCLUSIONS
  The data indicate that in RA patients being treated according to current dosing recommendations, the risk of developing CSA-induced nephropathy is low.
authors.affiliation: Sandoz Pharma AG, Basel, Switzerland.
authors.forename: F
authors.initials: F
authors.lastname: Rodríguez
authors.forename: J C
authors.initials: JC
authors.lastname: Krayenbühl
authors.forename: W B
authors.initials: WB
authors.lastname: Harrison
authors.forename: O
authors.initials: O
authors.lastname: Førre
authors.forename: B A
authors.initials: BA
authors.lastname: Dijkmans
authors.forename: P
authors.initials: P
authors.lastname: Tugwell
authors.forename: P A
authors.initials: PA
authors.lastname: Miescher
authors.forename: M J
authors.initials: MJ
authors.lastname: Mihatsch
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001706:Biopsy; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects*; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007668:Kidney / Q000187:drug effects* / Q000473:pathology; D007674:Kidney Diseases / Q000139:chemically induced* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D012307:Risk Factors
chemical_list: D018501:Antirheumatic Agents; D016572:Cyclosporine; D003404:Creatinine